RxDoctor Payments Data

Melissa Wilhelm, NP

Women's Health · Los Angeles, CANPI 1437609534

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,136in general payments, 2019–2025

Across 104 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$449
  • Bayer$346
  • Exeltis, USA Inc.$270
  • AbbVie$190
  • Organon$146
  • Baxter Healthcare$109
  • plus $626 from 14 others

What the payments were for

  • Food & beverage$2,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,136 in reported general payments places this provider in the 90th percentile of 480 women's health providers in California.

See all women's health providers in California

Medicare billing

Part B allowed, 2024
$3,894
Medicare patients
35
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol22$1,878
Metronidazole16$549
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$262

Paid to pharmacies, not to this prescriber.

Other women's health in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →